Cure Leukaemia
Cure Leukaemia is a UK national blood cancer charity that funds three clinical-trial networks (TAP, IMPACT, ATICUS) across 26+ hospitals, giving blood-cancer patients faster access to pioneering treatments and enrolling over 2,600 patients into studies.
- Company typePrivate
- Founded2003
- HeadquartersBirmingham, United Kingdom
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Cure Leukaemia does
Cure Leukaemia is a UK national blood cancer charity founded in 2003 by Professor Charlie Craddock CBE and headquartered in Solihull/Birmingham. Its core purpose is funding clinical-trial infrastructure that gives blood-cancer patients — adults and children — faster access to pioneering treatments. The charity operates three coordinated national research networks: the Trials Acceleration Programme (TAP), which links 15 blood-cancer centres covering a catchment area of 30 million people and has cut average trial set-up time from approximately 30 months to under one year; the IMPACT Network, which has enrolled more than 1,400 patients across UK transplant centres; and the ATICUS Network, launched in 2024 as the world's first national infrastructure dedicated to paediatric stem-cell transplant trials, bringing together 11 leading children's hospitals. Collectively these networks have enrolled over 2,600 patients into more than 22 studies and have secured over £100 million of free drugs for the NHS.
Cure Leukaemia's business model is donation-driven rather than commercial. Revenue streams include one-off and recurring individual donations (channel-led through the cureleukaemia.co.uk website), event-based fundraising (Tour 21 cycling challenge, Paris Marathon, Worcester City Run, Tour de 4, Run For A Cure, Cycle For A Cure, Fun For A Cure, Kids For ATICUS), and corporate partnerships. The flagship corporate programme is Club 10, a national business network in which companies pledge £10,000 annually, targeting £1 million of annual business contributions with Gary Lineker OBE as public patron. Marquee event sponsors include Specsavers and Flutter Entertainment (Tour 21), with PwC hosting the ATICUS Network launch in Manchester. The charity is structured as a company limited by guarantee registered in England and Wales (Company Number 4569174), led by CEO James McLaughlin, and operates with a lean 1-10 employee team focused on fundraising, programme management, and partner relations rather than in-house clinical delivery, which is executed through funded research nurses embedded in NHS partner hospitals.
Cure Leukaemia firmographics
Firmographics- Name
- Cure Leukaemia
- Legal name
- Cure Leukaemia
- Website
- https://cureleukaemia.co.uk
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cure Leukaemia is a UK national blood cancer charity that funds three clinical-trial networks (TAP, IMPACT, ATICUS) across 26+ hospitals, giving blood-cancer patients faster access to pioneering treatments and enrolling over 2,600 patients into studies.
- Ownership category
- akta.pro rank
Cure Leukaemia industry classification
Industry- Product category
- Blood Cancer Research Charity
- NAICS
- Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
- akta.pro secondary industries
- Health & Medical Research Grantmaking Foundations (BPAGAKAL), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)
Keywords
Where Cure Leukaemia is headquartered
LocationHeadquarters
- HQ city
- Birmingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices16 records
Markets served
Cure Leukaemia business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Individual Donations: One-time and recurring donations from individuals supporting blood cancer research and patient care.
- Club 10 Corporate Memberships: Businesses pledge £10,000 annually to support the ATICUS Network and other research initiatives. The initiative aims to raise £1 million annually through local business contributions.
- Event Fundraising: Revenue from participants in running, cycling, and other athletic events such as Tour 21, Paris Marathon, Worcester City Run, and Tour de 4.
- Corporate Partnerships: Sponsorship and partnership agreements with companies like Specsavers, Flutter Entertainment, and others for specific events and initiatives.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Club 10 Business Membership - £10,000 annually |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
Cure Leukaemia product offering
Product offeringCore offering
Cure Leukaemia is a national blood cancer charity that funds and operates clinical trial networks across UK hospitals, including the Trials Acceleration Programme (TAP), the IMPACT Network, and the ATICUS Network. It enables blood cancer patients to access pioneering, potentially life-saving treatments through specialist research nurses based at major UK treatment centres. The charity also mobilises public donations and corporate partnerships to sustain and expand these research and treatment-access programmes.
Product overview
Cure Leukaemia is a UK-based blood cancer research charity offering a portfolio of programs and services rather than a traditional product. The core offering consists of three interconnected clinical research networks: the Trials Acceleration Programme (TAP), the IMPACT Network, and the ATICUS Network (for paediatric patients). These are supported by fundraising initiatives including Club 10 corporate partnerships, events like Tour 21, Run For A Cure, and Cycle For A Cure, as well as patient-facing resources such as the Let's Talk Blood Cancer Podcast and Patient Hub. The organization funds specialist research nurses at hospitals across the UK to enable patients to access pioneering clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- Club 10: National business network that aims to raise £1 million annually through local business contributions of £10,000 per year to support blood cancer research and treatments.
- Trials Acceleration Programme (TAP)
- IMPACT Network
- ATICUS Network
- Let's Talk Blood Cancer
- Tour 21
Products and services
- Trials Acceleration Programme (TAP)
- IMPACT Network
- ATICUS Network
- Club 10
- Tour 21
- Run For A Cure
- Cycle For A Cure
- Fun For A Cure
Quantifiable outcome
- 1,200+ patients joined 22 clinical trials through TAP Network
- +4 more outcomes
Companies that use Cure Leukaemia
Customer profileNamed customers20 records
Segments5 records
Ideal customer profiles3 records
Cure Leukaemia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cure Leukaemia partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- SpecsaverscoreSpecsavers became an official partner for The Tour 21 in partnership with Flutter Entertainment. The brand has visible presence on official rider jerseys and team coach trailer. The partnership supports former employee Scott McGowan who is taking on the 21-stage challenge.
- Sir Chris HoycoreSix-time Olympic champion Sir Chris Hoy selected Cure Leukaemia as a charity partner for the Tour de 4 2026 cycling challenge. This partnership will help accelerate the opening of the ATICUS Network.
- Ultimate (Manchester Digital Agency)minorManchester-based digital agency Ultimate joined Cure Leukaemia's national business network Club 10, which supports research and treatments for childhood leukaemia. The initiative backed by Gary Lineker aims to raise £1 million annually through local business contributions.
- Flutter EntertainmentcoreFlutter Entertainment partners with The Tour 21, an annual cycling challenge that sees amateur cyclists complete the Tour de France route one week ahead of the professionals. Raises vital funds for pioneering clinical trials.
- Gary Lineker OBEcoreGary Lineker is Cure Leukaemia's patron, backed by his son George's history with leukaemia. He actively promotes the charity and the Club 10 initiative, using his platform to raise awareness and funds.
- Josh Tongue (England Cricketer)minorEngland fast bowler Josh Tongue serves as a Cure Leukaemia ambassador. Joined New Zealand cricketer Blair Tickner to show unified support during a test match at Trent Bridge, displaying support for the charity on their bats.
- James and Hannah Black (Club 10 Founders)coreFounding members of Club 10, James and Hannah Black committed to donating £10,000 annually for five years to support The ATICUS Network. Their son Keanu survived leukaemia after treatment at Southampton Children's Ward.
- PwCminorPwC hosted the ATICUS Network launch event in Manchester, bringing together businesses, clinicians, patients and families to mark the pivotal moment in the charity's mission to revolutionise treatment options for children with blood cancer.
Scale indicators10 records
Recent moves5 records
Expansion highlights5 records
Cure Leukaemia competitors and assessment
Company assessmentRegional players
- Leukaemia Foundation (Australia): The Leukaemia Foundation is Australia's leading blood cancer charity, funding research and supporting patients. Regional peer with the same disease focus and research-funding model, but operating in a different geography.
Direct peers
- Children with Cancer UK: Children with Cancer UK funds research into childhood cancers including leukaemia. Direct peer in the paediatric cancer research funding niche that ATICUS targets.
- Anthony Nolan: Anthony Nolan runs the UK's largest stem cell donor registry and funds transplant research, with overlapping mission in stem cell transplantation. Direct peer given shared focus on blood cancer treatment infrastructure and stem cell transplant research networks.
- Young Lives vs Cancer: Young Lives vs Cancer (formerly CLIC Sargent) supports children and young people with cancer, including blood cancers. Direct peer in paediatric cancer patient support and family services.
- DKMS: DKMS operates the world's largest stem cell donor registry and funds transplant-related research. Direct peer given shared focus on stem cell transplantation infrastructure and donor recruitment relevant to IMPACT and ATICUS networks.
- Blood Cancer UK: Blood Cancer UK is the UK's leading dedicated blood cancer charity, funding research and providing patient support. Direct peer given identical disease focus (leukaemia, lymphoma, myeloma), UK footprint, and research-funding mission.
- The Leukemia & Lymphoma Society: The Leukemia & Lymphoma Society is the US's largest voluntary health organization dedicated to blood cancer research and patient support. Direct international peer with the same disease focus and research-funding model.
Broad incumbents
- Macmillan Cancer Support: Macmillan is one of the UK's largest cancer charities, providing patient support and funding some research/services. Broad incumbent competing for the same donor base and corporate partnerships across the UK cancer community.
- Cancer Research UK: Cancer Research UK is the UK's largest cancer charity, funding broad research including blood cancer trials. Broader incumbent — competes for the same donor pound and pharma-funded trial placements but covers all cancers, not specialized in leukaemia.
Emerging players
- Worldwide Cancer Research: Worldwide Cancer Research funds early-stage cancer research globally. Smaller, research-focused peer that overlaps with Cure Leukaemia's research funding mission but operates across all cancer types rather than specializing in blood cancer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cure Leukaemia social profiles
Digital presenceCure Leukaemia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cure Leukaemia leadership team
Management profileNumber of profiles
Profiles4 records
Cure Leukaemia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cure Leukaemia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cure Leukaemia
What does Cure Leukaemia do?
Cure Leukaemia is a national blood cancer charity that funds and operates clinical trial networks across UK hospitals, including the Trials Acceleration Programme (TAP), the IMPACT Network, and the ATICUS Network. It enables blood cancer patients to access pioneering, potentially life-saving treatments through specialist research nurses based at major UK treatment centres. The charity also mobilises public donations and corporate partnerships to sustain and expand these research and treatment-access programmes.
Is Cure Leukaemia a public or private company?
Cure Leukaemia is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Cure Leukaemia founded?
Cure Leukaemia was founded in 2003. It employs 1 to 10 people.
Where is Cure Leukaemia based?
Cure Leukaemia is headquartered in Birmingham, United Kingdom, in the Europe region.
How does Cure Leukaemia make money?
Four revenue lines are on record. Individual Donations are the primary driver. The others are club 10 Corporate Memberships, event Fundraising and corporate Partnerships.
Who are Cure Leukaemia's main competitors?
Leukaemia Foundation (Australia) is listed as a regional player. Direct peers are Children with Cancer UK, Anthony Nolan, Young Lives vs Cancer, DKMS, Blood Cancer UK and The Leukemia & Lymphoma Society. Broad incumbents are Macmillan Cancer Support and Cancer Research UK. Worldwide Cancer Research is listed as an emerging player.
Does Cure Leukaemia have an API?
No public API is recorded for Cure Leukaemia.
What industry is Cure Leukaemia in?
Cure Leukaemia's product category is Blood Cancer Research Charity. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8000.